Skip to main content
11/12/2023

The NanoDIRE-CT project progresses toward targeted tumor stem cell therapy using nanobodies

Equip de NanoDIRE-CT

NanoDIRE-CT team at Vall d'Hebron.

11/12/2023

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Vall d’Hebron Research Institute (VHIR) and ZeClinics work together in the NanoDIRE-CT project, which aims to use an innovative method based on nanobodies, that is, antibody fragments with small size, for targeted tumor stem cell therapy.

During the last year, efforts have been focused on demonstrating the remarkable capability of meticulously chosen nanobodies. These nanobodies have proven instrumental in impeding the relentless growth of both Cancer Stem Cells (CSC) and Differentiated Cancer Cells within the innovative zebrafish xenotransplantation model*. From an extensive bacterial library, three extraordinary nanobody candidates have emerged, exhibiting potent anticancer properties.

The researchers have found a robust affinity for binding with CSC in vitro, coupled with a notable absence of adverse effects post-injection into the duct of Cuvier. This marks an important milestone in our pursuit of a potential breakthrough in cancer treatment.

Together, VHIR and ZeClinics have worked tirelessly to amplify the production of Nanobodies and assess their potential as powerful anti-oncogenic agents. The seamless coordination has been pivotal in managing and supervising this groundbreaking project.

Through the collaboration’s unwavering commitment, they’ve not only augmented production but also conducted thorough purification, subjecting these nanobodies to rigorous High-Performance Liquid Chromatography analysis to precisely identify their target interactions.

The project is funded by the State Research Agency under the Ministry of Science, Innovation and Universities; program Retos Colaboracion 2019, project reference: RTC2019-006809-1.

*Institutional Declaration on the Use of Animals in Research

Related news

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Related professionals

Ibane Abasolo Olaortua

Ibane Abasolo Olaortua

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Fernanda Raquel Da Silva Andrade

Fernanda Raquel Da Silva Andrade

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Albert Blanco Grau

Albert Blanco Grau

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Daniel Bravo Nieto

Daniel Bravo Nieto

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.